News

FDA Offers New Resource on Biosimilars for Health Care Providers (copy 1)


 

References

A free continuing education course, FDA Overview of Biosimilar Products, is available to health care providers. The course was designed to help providers strengthen their knowledge and understanding of biosimilars and interchangeable products, which are not the same as generic products.

In February 2015, the FDA approved the first biosimilar in the U.S., and there is growing interest in biosimilars in the pharmaceutical industry. The new course will help health care professionals understand how a biosimilar can be prescribed and dispensed, and how and when an interchangeable product can be substituted for another biological product.

The course is available to health professionals on FDA’s CDERLearn website and can be completed on a tablet for those not at their desktop computer. Click for more information.

Recommended Reading

New Study Identifies Class of Drugs That Removes Abnormal Proteins in Brain and Improves Memory in Mice
MDedge Neurology
Global CNS Gene Therapy Clinical Trial Is Underway at NIH
MDedge Neurology
Mavoglurant disappoints in fragile X trials
MDedge Neurology
Dravet Syndrome Incidence Is Twice That of Prior Estimate
MDedge Neurology
Human gene editing consensus study underway
MDedge Neurology
Elevated cardiovascular risks linked to hidradenitis suppurativa
MDedge Neurology
COMMENTARY—Another Candidate for Diagnosing Myasthenia Gravis
MDedge Neurology
Test Accurately Diagnoses Myasthenia Gravis
MDedge Neurology
Brazilian study identifies fetal abnormalities linked to Zika virus
MDedge Neurology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Neurology